Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Healthy Participants
Interventions: LY4064809 Test Formulation, LY4064809 Reference Formulation; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Sunscreening Agents
Interventions: BAY987521; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Healthy Volunteers
Interventions: Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Non-small Cell Lung Cancer
Interventions: Pertuzumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 8
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 5 more

Conditions: Osteoarthritis
Interventions: Fortetropin supplement, Cheese protein; Other
Lead sponsor: MYOS Corp; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions: GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Heart Failure, Overactive Bladder, Incontinence
Interventions: Extended release torsemide, Immediate release torsemide, Extended release torsemide placebo, Immediate release torsemide placebo; Drug
Lead sponsor: Sarfez Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sunscreening Agent
Interventions: Coppertone (BAY987516); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Inactivated Influenza Vaccine
Interventions: 2005-2006 trivalent inactivated influenza vaccine; Biological
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 42 Days to 84 Days
Enrollment: 1,375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: aflibercept, High-dose aflibercept; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 84
States / cities: Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 78 more

Conditions: Solid Tumors
Interventions: Idasanutlin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 9
States / cities: Aurora, Colorado • New Haven, Connecticut • St Louis, Missouri + 5 more

Conditions: Neoplasms
Interventions: BXQ-350; Drug
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Lexington, Kentucky • Cincinnati, Ohio • Columbus, Ohio

Conditions: Healthy Volunteers, Vitamin A
Interventions: Unfortified bouillon plus vitamin A in oil, Bouillon fortified with vitamin A #1 plus unfortified oil, Bouillon fortified with vitamin A #2 plus unfortified oil; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Seltorexant; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chikungunya Virus Infection
Interventions: CHIKV VLP vaccine booster, Placebo booster; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 12 Years and older
Enrollment: 715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 24
States / cities: Mobile, Alabama • Tempe, Arizona • Melbourne, Florida + 20 more

Conditions: Healthy
Interventions: Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation, Rabeprazole tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: ICU Acquired Weakness
Interventions: FDY-5301, Placebo; Drug · Other
Lead sponsor: Faraday Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Torrance, California • Gainesville, Florida • Boston, Massachusetts + 2 more

Conditions: Alzheimer Disease
Interventions: AC-OLE-01-VA; Drug
Lead sponsor: Cerecin; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Schizophrenia
Interventions: Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 937 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 39
States / cities: Cerritos, California • Escondido, California • Garden Grove, California + 31 more

Conditions: Aging, Inflammation
Interventions: LLP-01, Placebo; Dietary Supplement · Other
Lead sponsor: LL Prosper Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Coronavirus (SARS-CoV)
Interventions: Aluminum hydroxide, Placebo, SARS-CoV; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertrophic Scar
Interventions: Pentamidine Isethionate, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers
Interventions: AGN-223575 Formulation A, AGN-223575 Formulation B, AGN-223575 Formulation C, AGN-223575 Vehicle; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Myelofibroses
Interventions: TP-3654; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Search by objective public record fields.

A Study of LY4064809 in Healthy Adult Participants

18475 - Sun Protection Factor Assay

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy

A Randomized, Double-Blind, Controlled Trial to Assess the Efficacy of a Fortetropin Supplement in Improving Symptoms of Osteoarthritis

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

Sun Protection Factor Assay

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors

Continued Treatment for Participants Enrolled in Studies of BXQ-350

Evaluation of Vitamin A Absorption From Fortified Bouillon

A Study of Seltorexant in Healthy Participants

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

Evaluation of FDY-5301 in Major Trauma Patients in ICU

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory and Cardiovascular Biomarkers in Healthy, Older Individuals.

SARS Coronavirus Vaccine (SARS-CoV)

Hypertrophic Scar Prevention by Novel Topical Gel Application

A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects

TP-3654 Food Effect Study